Matthew D. Ronsheim, PhD
Chief Operating Officer
Dr Matthew Ronsheim became our Chief Operating Officer in August 2024. With more than 25 years of experience, he has a proven track record of advancing medicines from discovery through clinical development, regulatory approvals, and commercial launch. Prior to joining Xenon, he was the President of Innoviva Specialty Therapeutics and previously served as its Chief Technical Officer. Before that, he was President of Entasis Therapeutics, which was acquired by Innoviva, and guided the company’s successful integration to create Innoviva Specialty Therapeutics. Matt also held senior leadership roles at Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories, where he contributed to the development and commercialization of important new therapies across several disease areas, including neurological disorders, infectious disease, and gastrointestinal conditions. He holds a BS in chemistry from Southern Connecticut State University and a PhD in synthetic organic chemistry from the University of New Hampshire.